Clinical and Translational Research
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1567-1594
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1567
Cellular senescence throws new insights into patient classification and pharmacological interventions for clinical management of hepatocellular carcinoma
Hou-Hong Wang, Wen-Li Chen, Ya-Yun Cui, Hui-Hui Gong, Heng Li
Hou-Hong Wang, Wen-Li Chen, Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou 236800, Anhui Province, China
Ya-Yun Cui, Department of Cancer Radiotherapy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei 230000, Anhui Province, China
Hui-Hui Gong, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, United Kingdom
Heng Li, Department of Comprehensive Surgery, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of USTC, Hefei 230000, Anhui Province, China
Author contributions: Wang HH and Chen WL contributed equally to this work; Li H conceived and designed the study; Wang HH and Chen WL conducted most of the experiments and data analysis, and wrote the manuscript; Cui YY and Gong HH participated in collecting data and helped to draft the manuscript; All authors reviewed and approved the manuscript.
Supported by Project of Bozhou Municipal Health Commission, No. bzwj2022A001; Project of Bozhou Science and Technology Bureau, No. bzzc2022008; and Scientific Research Fund of Bozhou Hospital, Anhui Medical University, No. by2022001.
Institutional review board statement: The study was approved by the Ethics Committee of The Affiliated Bozhou Hospital of Anhui Medical University, No. 2022-17.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: The data used to support the findings of this study are included within the supplementary information files.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Heng Li, Doctor, Professor, Department of Comprehensive Surgery, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of USTC, No. 17 Lujiang Road, Hefei 230000, Anhui Province, China. jxna36@163.com
Received: February 13, 2023
Peer-review started: February 13, 2023
First decision: May 23, 2023
Revised: July 10, 2023
Accepted: August 6, 2023
Article in press: August 6, 2023
Published online: September 15, 2023
Core Tip

Core Tip: Cellular senescence, a state of stable growth arrest, is implicated in human cancers. Nevertheless, characterization of cellular senescence-associated phenotypes in hepatocellular carcinoma (HCC) is still indistinct. Here, we proposed a novel cellular senescence-based classification for HCC and identified TRNP1 as a novel therapeutic target.